MPR Weekly Dose
By MPR Weekly Dose
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by MPR Weekly Dose
Category: Health & Fitness
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 8
Reviews: 0
Episodes: 274
Description
Each week the MPR team brings you the top stories from the world of medicine and pharma in a matter of minutes. With 35 years of publishing drug information behind us, you can rely on MPR to provide accurate and up-to-date news.
| Episode | Date |
|---|---|
|
MPR Daily Dose #275 — Top OTC Meds and Products; FDA Assess Safety in Pregnancy; Efgartigimod gMG Indication Broadened; R/R Mantle Cell Lymphoma Approval; ALS Treatment Fast Tracked
|
May 15, 2026 |
|
MPR Weekly Dose Podcast #274 — Ozempic Tablets; ALS Tx Fast Tracked; Phase 3 results for aficamten in HCM; Motion Sickness Drug Approved; Lantus Alternative
|
May 08, 2026 |
|
MPR Weekly Dose Podcast #273 — Gene Therapy Approved for Rare Hearing Loss; Pattern Hair Loss Tx Shows Growth; Brestri for Asthma; CRISPR gene for HAE; Novel Obesity Tx
|
May 01, 2026 |
|
MPR Weekly Dose Podcast #272 — Idvynso Approved for HIV; Expanded Indication for Dupixent; Novel Tx Shows Promise for Pancreatic CA; Oral Semaglutide for Adolescents; GLP-1 Potential Knee OA Tx
|
Apr 24, 2026 |
|
MPR Weekly Dose Podcast #271 — Foundayo Now Available, Meets Safety Endpoints; Filspari, Sdamlo Approved; FDA Encourages TRT Makers to Purse Label Expansion
|
Apr 17, 2026 |
|
MPR Weekly Dose Podcast #270 — High Dose Wegovy; Durvalumab Combo for Unresectable HCC; Generic Dapagliflozin; Yuviwel Now Available for Achondroplasia
|
Apr 10, 2026 |
|
MPR Weekly Dose Podcast #269 — Lifyorli, Avlayah Approved; Lyme Disease Vaccine Trial Results; Once-Weekly Basal Insulin Approved for T2DM
|
Mar 27, 2026 |
|
MPR Weekly Dose Podcast #268 — Childhood Immunization Schedule Changes Blocked; High Dose Wegovy Gets Green Light; Hidradenitis Suppurativa Tx Indication Expanded; Triple Therapy Show Significant Weight Loss
|
Mar 20, 2026 |
|
MPR Weekly Dose Podcast #267 — Sotyktu, Leucovorin Gain Approval; Follicular Lymphoma Treatment Withdrawn; FDA to Review Potential Hypertension Drug
|
Mar 12, 2026 |
|
MPR Weekly Dose Podcast #266 — Generic Flovent HFA; Achondroplasia Tx Gains Approval; Dupixent Approved for Allergic Fungal Rhinosinusitis; Swallowable Gastric Balloon
|
Mar 06, 2026 |
|
MPR Weekly Dose Podcast #265 — Wakix Approval Expanded; Psoriasis, Weight-Loss Combo Tx; Psilocybin Shows Promise in TRD; Remibrutinib for Chronic Inducible Urticaria; Injectable Regimen Benefits HIV Treatment Adherence
|
Feb 20, 2026 |
|
MPR Weekly Dose Podcast #264 — Hep B Birth Dose Study; FDA Approves Treatments for Pancreatic, Ovarian Cancer; Priority Review for Narcolepsy Treatment
|
Feb 13, 2026 |
|
MPR Weekly Dose Podcast #263 — Combo Tx Shows Superior Weight Loss; Amgen Refuse to Withdraw Drug; Legal Action Threatened Against Hims & Hers; Film Approved for ED; NDA for mCRC accepted for review
|
Feb 06, 2026 |
|
MPR Weekly Dose Podcast #262 — Docs Turn to AAP's Vaccine Schedule; Safety Alert for Burn, Wound Products; SC Lecanemab to Be Reviewed; Cardamyst Nasal Spray Available; Gene Therapies Placed on Hold
|
Jan 30, 2026 |
|
MPR Weekly Dose Podcast #261 — New Research on Prenatal Acetaminophen Use; Chikungunya Vaccine Withdrawn; Nexplanon Use Extended; GLP-1 RAs and Suicidal Behavior; At-Home Device for Depression
|
Jan 23, 2026 |
|
MPR Weekly Dose Podcast #260 — Top 2026 Health Trends With US News' Annika Urban
|
Jan 16, 2026 |
|
MPR Weekly Dose Podcast #259 — ACIP Hep B Recommendation; Retatrutide Shows Promise; Omisirge Approved; Counterfeit Ozempic Seized; Gene Tx Approved for Wiskott-Aldrich Syndrome
|
Dec 12, 2025 |
|
MPR Weekly Dose Podcast #258 — Jaypirca Gains Expanded Approval; Allograft to Restore Nerve Function; Baxdrostat Gets Priority Review; Stargardt Tx Shows Promise; Edema Autoinjector Accepted for Review
|
Dec 05, 2025 |
|
MPR Weekly Dose Podcast #257 — Tonmya Available; Elevidys Safety Warning; Mitapivat SCD Trial Results; Redemplo Approved for FCS; Hyrnuo Granted Accelerated Approval
|
Nov 21, 2025 |
|
MPR Weekly Dose Podcast #256 — HRT Label Changes; Calypta Approved for MDD; Darzalex Faspro Indication Expanded; MS Tx Potential; Simplified HIV Regimen
|
Nov 14, 2025 |
|
MPR News Weekly Dose #255 — Fluoride Supplements Restricted; AAP Leucovorin Statement; At-Home Ultrasound; Kygevvi Approved; Gazyva Lupus Trial Results
|
Nov 07, 2025 |
|
MPR Weekly Dose #254 — Tranexamic Acid Label Change; New Tezspire Approval; Psychedelic Gains Breakthrough; Oral Semaglutide for MACE Reduction; Gazyva Approved for Lupus
|
Oct 24, 2025 |
|
MPR Weekly Dose Podcast #253 — Bipolar I Treatment; Blood-Based Test for Alzheimer Disease; UC Tx Approved for Pediatrics; Rinvoq Expanded; Oral Glucagon-Like Peptide-1
|
Oct 17, 2025 |
|
MPR Weekly Dose Podcast #252 — CDC Approves New Immunization Sched; Novel Furosemide Delivery Device; New IPF Treatment Approved; Libtayo approved for CSCC; Breakthrough Therapy for influenza
|
Oct 10, 2025 |
|
MPR Weekly Dose Podcast #251 — Qivigy for Primary Humoral Immunodeficiency; Near Vision Eyedrops; Tremfya Expanded; Meth Intoxication Tx; Alzheimer Disease Tx Fast Tracked
|
Oct 03, 2025 |
|
MPR Weekly Dose Podcast #250 — Changes to MMRV Recs; Trump Admin Links Acetaminophen to Autism; Forzinity Accelerated Approval; Huntington Disease Breakthrough; SC Formulation of Keytruda
|
Sep 26, 2025 |
|
MPR Weekly Dose Podcast #249 — Device for Asherman Syndrome; Novel Oral GLP-1 Trial Results; Nasal Spray for Edema; Capvaxive in Adolescents; Ocaliva Withdrawn
|
Sep 19, 2025 |
|
MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated
|
Aug 29, 2025 |
|
MPR Weekly Dose Podcast #248 — COVID-19 Vaccines Approved for Upcoming Season; CDC Leadership in Turmoil; Pill Reduces Body Weight; Ixchiq Use Suspended; Filspari REMS Updated
|
Aug 29, 2025 |
|
MPR Weekly Dose Podcast #247 — AAP Release Pediatric Immunization Schedule; Blood Pressure MGMT Guideline; Wegovy Approved for Noncirrhotic MASH; New Fibromyalgia Tx; Investigational Sickle Cell Tx Fails to Meet Endpoint
|
Aug 21, 2025 |
|
MPR Weekly Dose Podcast #246 — Device Cleared for Sleep Apnea; Skysona Safety Update; Non-Cystic Fibrosis Bronchiectasis Tx; Animal-Derived Thyroid Meds Safety Update; Synagis Discontinued
|
Aug 15, 2025 |
|
MPR Weekly Dose Podcast #245 — Label Change for Opioids; Results From Weight-Loss Pill Trial; Ajovy Approved for Some Peds; Ixchiq Vaccine Restrictions Lifted; Modeyso Approved for Rare Brain Tumor
|
Aug 07, 2025 |
|
MPR Weekly Dose Podcast #244 — Treatment Approved for Two Rare Kidney Diseases; Elevidys Can Resume Shipments for Ambulatory Patients; Mounjaro Shows Cardio Benefits; New Wearable Cardiac Monitor Cleared; Hair Regrowth With Upadacitinib
|
Aug 01, 2025 |
|
MPR Weekly Dose Podcast #243 — Sarepta Pauses Elevidys Shipments; Advisory Committee Votes Against PTSD Tx; Rapiblyk Now Available; Pill for Sleep Apnea; JUUL Cigs Authorized
|
Jul 25, 2025 |
|
MPR Weekly Dose #242 — New indication for Kerendia; investigational Tx shows promise for hypertension; Novolog biosimilar; trial results for hormone-free contraceptive; new prefilled Shringrix syringe
|
Jul 18, 2025 |
|
MPR Weekly Dose Podcast #241 — RFK Jr Sued Over Vaccine Policy Changes; Hereditary Angioedema Tx Approved; New OTC Blood Pressure Monitor; Kisunla Dosing Regime; REMS removed for ERA meds
|
Jul 11, 2025 |
|
MPR Weekly Dose Podcast #240 — Wristband to Improve Tremors; Weight Loss Risk With ADHD Meds; REMS Eliminated for CAR T-Cell Immunotherapies; Zegfrovy Approved; New CDC Advisory Committee Has First Meeting
|
Jul 04, 2025 |
|
MPR Weekly Dose Podcast #239 — Novo Nordisk Cut Ties With Hims & Hers; Updates to Label for Imaging Agent Vizamyl; Subcutaneous Autoinjector for Lupus; Psilocybin for Treatment-Resistant Depression; Sotatercept Phase 3 PAH Results
|
Jun 27, 2025 |
|
MPR Weekly Dose Podcast #238 — Nucala New Indication; FDA To Make COVID-19 Vaccines Harder to Obtain; Pruritus Reported With Allergy Med Discontinuation; Oral Antibiotic for cUTIs; Investigational Celiac Tx Fast Tracked
|
May 30, 2025 |
|
MPR Weekly Dose Podcast #237 — At-Home Cervical CA Screening; FDA Assess Removing Fluoride Products; Chikungunya Vaccination Pause; SC Inj. for Migraine Tx; Gene Therapy for Hunter Syndrome
|
May 15, 2025 |
|
MPR Daily Dose Podcast #236 — Needle-Free Epinephrine for Peds; Oral Semaglutide for Weight Mgmt; Wearable Defibrillator; Hypertension Tx Approved; Stelara Biosimilar
|
May 09, 2025 |
|
MPR Weekly Dose Podcast #235 — Rinvoq Approval Expanded; Wegovy Telehealth Link-Up; Epidermolysis Bullosa Wound Healing Tx; Imaavy Approved for gMG; Nasal Powder to Treat Migraines
|
May 02, 2025 |
|
MPR Weekly Dose Podcast #234 — Alert for Compounded Finasteride; Cytisinicline Improves Smoking Cessation; GERD Tx Shows Promise; ACIP Makes New Vaccine Recs
|
Apr 25, 2025 |
|
MPR Weekly Dose Podcast #233 — Pfizer ends development of weight loss drug; counterfeit Ozempic seized; daily pill demonstrates HbA1c reductions; mavacamten misses trial endpoint; smart belt to reduce fall injury
|
Apr 18, 2025 |
|
MPR Weekly Dose Podcast #232 — Uplizna gains new approval; Vanrafia approved for proteinuria in IgAN; schizophrenia ER Tx now available; Imcivree shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk
|
Apr 11, 2025 |
|
MPR Weekly Dose Podcast #231 — Treatment for hyperphagia in Prader-Willi Syndrome; Qfitlia Approved; Chlamydia Vaccine and OTC Test; Semaglutide Improves Walking; Imfinzi Approved for MIBC
|
Apr 04, 2025 |
|
MPR Weekly Dose Podcast #230 — New Antibiotic for uUTIs; Treatment Approved for Advanced Neuroendocrine Tumors; New Rosacea Tx Option; Tremfya Gains Crohn Disease Indication; Dept. of HHS Cuts 10,000 Jobs
|
Mar 28, 2025 |
|
MPR Weekly Dose Podcast #229 — Flu Vaccine Recommendations; Patient Dies Following Gene Therapy; Chikungungya Vaccine; Zunveyl Available; REMS Removed for Tryvio
|
Mar 21, 2025 |
|
MPR Weekly Dose Podcast #228 — Xolair biosimilar approved; Furoscix indication expanded; Novel implant for rare eye disease; Lorundrostat trial data; Elevated benzene in acne treatments
|
Mar 14, 2025 |
|
MPR Weekly Dose Podcast #227 — Labeling Changes for Testosterone Products; Food Allergy Treatments Compared; FDA Approves Stroke Tx; COVID-19, Flu Vaccine Effectiveness for Recent Season; Neffy 1mg Approved
|
Mar 06, 2025 |
|
MPR Weekly Dose Podcast #226 — REMS Removed for Schizophrenia Tx; New Copper Intrauterine Device; Wegovy, Ozempic Supply Update; Lumbar Disc Disease Tx Fast Tracked; Tourette Syndrome Shows Promise
|
Feb 28, 2025 |
|
MPR Weekly Dose 225 — New Vaccine Approvals; Skin Prep Recalled; Insulin Biosimilar Approved; Twice-yearly lenacapavir to be reviewed
|
Feb 20, 2025 |
|
MPR Weekly Dose Podcast #224 — Strategy for High-Threshold Peanut Allergy; Emblaveo Approved for Complicated Infections; New Formulation of Evrysdi; FDA Fast Tracks Designations Investigational Agents for Alzheimer Disease and Cannabis Use Disorder.
|
Feb 13, 2025 |
|
MPR Weekly Dose 223 — Diabetes Devices Alert Warning; Continuous Apomorphine Device Approved for Parkinson Disease; Symbravo Approved; New Pain Tx; Propranolol May Cut Stroke Risk
|
Feb 07, 2025 |
|
MPR Weekly Dose 222 — Ozempic expanded approval; MS treatment gets Boxed Warning; Monotherapy approval for Spravato; Alzheimer Tx maintenance regimen; Enhertu new Breast CA indication
|
Jan 30, 2025 |
|
MPR Weekly Dose Podcast #221 — OTC Phenylephrine Removal; Schizophrenia Drug Efficacy Data; FDA Vote on Sotagliflozin; IV Ibuprofen vs Ketorolac; Semaglutide Improves Liver Fibrosis
|
Nov 08, 2024 |
|
Illegal Online Pharmacies: An interview with Libby Baney, senior advisor to the Alliance for Safe Online Pharmacies
|
Nov 04, 2024 |
|
MPR Weekly Dose Podcast #219 — Hurricane Helene Impacts IV Supply; At-Home COVID/Flu Test; Fake Online Pharmacies; Depression Tx Fast Tracked; Cologuard Plus Cleared
|
Oct 11, 2024 |
|
MPR Weekly Dose Podcast #218 — Novel Weight Management Tx; Complete Response Letter for Tradipitant; Apple's Sleep Apnea Feature Cleared; New Keytruda Indication; Ebglyss for Atopic Dermatitis
|
Sep 20, 2024 |
|
MPR Weekly Dose Podcast #217 — Novel Ulcerative Colitis Tx; Once-Weekly Insulin Efsitora in T1D; Dupilumab for Urticaria; Ultra-Long Acting Biologic in Asthma; Results for Herpes Vaccine
|
Sep 13, 2024 |
|
MPR Weekly Dose Podcast #216 — Vaccine Guidance for Flu Season; Mpox Vaccine; Updated Novavax Vaccine Authorization; OTC Gel for ED; New Insertion Device for Paragard
|
Sep 06, 2024 |
|
MPR Weekly Dose Podcast #215 — HIV Drug Discontinuation; Combo for EGFR-Mutated NSCLC; Update on Unapproved Potassium Phosphates in Peds; Otezla Indication Expanded; Tirzepatide Diabetes Risk Reduction Trial
|
Aug 23, 2024 |
|
MPR Weekly Dose Podcast #214 — Livdelzi Approved for PBC; Novel Prurigo Nodularis Tx; FDA Denies MDMA Therapy; Yorvipath Approved; Digital Therapy for MDD
|
Aug 16, 2024 |
|
MPR Weekly Dose Podcast #213 — Obesity Drug Shortage Update; Updated Contraceptive Recs; Synovial Sarcoma T-Cell Tx; Lymphir Approved; Fabhalta Gains a New Indication
|
Aug 09, 2024 |
|
MPR Weekly Dose Podcast #212 — Compounded Semaglutide Errors; New Alzheimer Disease Tx; Test for Colorectal Cancer; Leqselvi Approved for Alopecia; Palforzia Expanded Approval
|
Aug 02, 2024 |
|
MPR Weekly Dose Podcast #211 — Duvyzat Available; Device to Treat Nasal Congestion; Pediatric Tx to Delay Diabetes; Soliris Biosimilar; First Orally-Disintegrating Contraceptive
|
Jul 26, 2024 |
|
MPR Weekly Dose Podcast #210 — Clonazepam ODT Recall; Parkinson Disease Tx Gets Fast Tracked; Pancreatic CA Vaccine; Voquenzna New Approval; Endari Generic
|
Jul 19, 2024 |
|
MPR Weekly Dose Podcast #209 — Atopic Dermatitis Topical; Wet AMD Implant Available Again; Neurostimulation Device for RA; FDA Denies Weekly Insulin; Smarthphone Therapy for Fibromyalgia
|
Jul 12, 2024 |
|
MPR Weekly Dose Podcast #208 — Ohtuvayre Approved; Generic Victoza; DMD Gene Therapy Expanded; Treatment for Pediatric Narcolepsy; OTC Video Game for ADHD
|
Jun 28, 2024 |
|
MPR Weekly Dose Podcast #207 — Skyrizi for UC; 21-Valent Pneumococcal Vaccine; Indictment May Affect ADHD Meds; Next-Gen COVID-19 Vaccine; Farxiga Approval Expanded
|
Jun 21, 2024 |
|
MPR Weekly Dose 206 — OTC Glucose Monitors; RSV Vaccine Approval Expanded; Juvenile Idiopathic Arthritis Tx; Emflaza Generic; New Primary Biliary Cholangitis Tx
|
Jun 14, 2024 |
|
MPR Weekly Dose Podcast #205 — Entresto Generics; mRNA-Based RSV Vaccine; Doxycycline PEP for STI Prevention; FDA Vote on MDMA Therapy; Rinvoq Indication Expanded
|
Jun 07, 2024 |
|
MPR Weekly Dose 204 — Novel ADHD Extended-Release Tx; Soliris Biosimilar Approved; Depression, Insomnia Tx; FDA Vote on Colorectal CA Test; Mistrust in the FDA
|
May 31, 2024 |
|
MPR Weekly Dose Podcast 203 — Urinary Incontinence Device; Autoinjector Warning for MS Tx; COVID-19 Preexposure Prophylaxis; Elyea Biosimilars; Lung Cancer Treatment Approved
|
May 24, 2024 |
|
MPR Weekly Dose 202 — Unreliable COVID-19 Tests; Insulin Pump App Update; Noninvasive Colorectal CA Test; Self-Collection HPV Screening Option; Drug Threats to the US
|
May 17, 2024 |
|
Drug Shortage Crisis: An interview with Dr. Michael Ganio
|
May 10, 2024 |
|
Psilocybin for Depression: An interview with Dr. Charles Raison
|
Apr 30, 2024 |
|
MPR Weekly Dose 199 — Fasenra Expanded Approval; HIV Tx Approval Expanded; ALS Drug Discontinued; CRL for Apomorphine Device; At-Home Mpox Test
|
Apr 12, 2024 |
|
MPR Weekly Dose 198 — Prescription App for MDD; Traumatic Brain Injury Blood Test; New Bloodstream Infection Antibiotic; Mpox Vaccine Availability; Left Ventricular Ejection Fraction Detection
|
Apr 05, 2024 |
|
MPR Weekly Dose 197 — Pemgarda Emergency Use; Expansion of Nexletol, Nexlizet; DMD Drug Approval; First Molecular Malaria Blood Test; OTC Topical Analgesic Warning
|
Mar 29, 2024 |
|
MPR Weekly Dose 196 — Chronic Rhinosinusitis Nasal Spray; Novel hypertension Tx; Stem-Cell Treatment Approved for Rare Disease; Accelerated approval for NASH Tx; Automated Insulin Delivery System
|
Mar 22, 2024 |
|
MPR Weekly Dose 195 — Weight Loss Tx Gains Cardiovascular Indication; Paxlovid Update; Psilocybin Granted Breakthrough Therapy; Decision Delay for Alzheimer Tx; Relyvrio Trial Results
|
Mar 15, 2024 |
|
MPR Weekly Dose 194 — OTC Birth Control Pill; First OTC Continuous Glucose Monitor; Influenza Vaccine for 2024/2025 Season; Breakthrough Therapy for LSD; Biosimilars to Prolia and Xgeva
|
Mar 08, 2024 |
|
MPR Weekly Dose 193 — Pepaxto Approval Withdrawn; Abrysvo Efficacy; Ixchiq Vaccine Recommendations; Novel Schizophrenia Tx Decision; UTI Tx Approval; Eye Ointment Recalled
|
Mar 01, 2024 |
|
MPR Weekly Dose 192 — Xolair Approved for Multiple Food Allergies; Amtagvi Gets Approval; Vit D Supplement Recalled; Cannabidiol for Pericarditis; Smartwatch Warning
|
Feb 23, 2024 |
|
MPR Weekly Dose 191 — First FDA-Approved Tx for Frostbite; New Eosinophilic Esophagitis Tx; Psychoactive Accepted for Review for PTSD; Novel Tx for Prurigo Nodularis; OTC Oximeter
|
Feb 16, 2024 |
|
MPR Weekly Dose 190 — Nonopioid Pain Med; Dental Pain Management; Arexvy Review; Magrolimab Development Ended; Athlete's Foot Spray Recalled
|
Feb 09, 2024 |
|
MPR Weekly Dose 189 — Alzheimer Drug Discontinued; New Acne Vulgaris Guidelines; Paxlovid Update; ADHD Drug Recall; Safety Alert for Copycat Eye Drops
|
Feb 02, 2024 |
|
MPR Weekly Dose 188 — Labeling Changes for T-Cell Immunotherapies; Novel Opioid Therapy; Boxed Warning for Prolia; At-Home Insemination Kit; Novel Rescue Inhaler
|
Jan 26, 2024 |
|
MPR Weekly Dose 187 — Gene Therapy for TDT; HyQvia Approved for CIDP; Handheld Skin Assessing Device; Vertebral Strength Device for Low-Bone Mass; Narcan Shelf-Life Extended
|
Jan 19, 2024 |
|
MPR Weekly Dose 186 — Diabetes Tx Suicidal Ideation Link Examined; Topical Molluscum Contagiosum Tx; Superpotent IV Bags Recalled; Syphilis Treatment Update; Menstrual Blood to Measure HbA1c
|
Jan 12, 2024 |
|
MPR Weekly Dose 185 — Best Diets for 2024; Counterfeit Ozempic; Myasthenia Gravis Tx Approved; Herpes False Positive Test Results; Promethazine Hydrochloride Safety Concerns
|
Jan 05, 2024 |
|
MPR Weekly Dose 184 — Gel Approved for EB Wounds; 21-Valent Pneumococcal Vaccine; Prescription Game Therapy for ADHD; HIV-Protecting Vaginal Insert; Multiple Food Allergy Drug
|
Dec 21, 2023 |
|
MPR Weekly Dose 183 — Updated Diabetes Guidelines; Novel Blood Collection Device; Postpartum Depression Tx; Male Birth Control Study; Approval Sought for Psychoactive Drug
|
Dec 15, 2023 |
|
MPR Weekly Dose Podcast #182 — Novel Weight Loss Tx; Safety Risks for Compounded Semaglutide; Fabhalta Approved for PNH; At-Home Insemination Kit; Sleep Apnea Device Cleared
|
Dec 08, 2023 |
|
MPR Weekly Dose Podcast #181 — Serious Reactions to Seizure Treatments; Desmoid Tumor Tx; Secondary CAR T-Cell Malignancies; Immunosuppressive Recall; CPAP Machine Issues
|
Dec 01, 2023 |
|
MPR Weekly Dose Podcast #180 — Chikungunya Vaccine; Amazon FDA Warning; At-Home STD Test; Lymphoma Drug Withdrawn; Antimicrobial Catheter Lock Solution for CRBSI
|
Nov 17, 2023 |
|
MPR Weekly Dose Podcast #179 — Weight Management Tx; Levemir Discontinued; Renal Denervation System Approved; Gene Therapy Fasted Tracked; Hidden Drugs in Glucose Supplement
|
Nov 10, 2023 |
|
MPR Weekly Dose Podcast #178 — FDA Flags Eye Drops; Ped Alert for COVID-19 Vaccine; Novel Heartburn Tx; Biosimilar to Stelara Approved; Anti-Fentanyl Monoclonal Antibody
|
Nov 03, 2023 |
|
MPR Weekly Dose Podcast 177 — Penbraya Approved; COVID-19 Therapy Shelf-Life Extended; New Formulation for IBD Tx; Self-Admin FluMist; Nonopioid Combo for Postop Pain
|
Oct 27, 2023 |
|
MPR Weekly Dose 176 — Novel MDD Tx; Panel Votes Against ALS Therapy; Preservation-Free Iyuzeh; RSV Vaccine Recommended for During Pregnancy; Investigative Tx Shows Promise in FCS
|
Sep 29, 2023 |
|
MPR Weekly Dose 175 — Xacduro Now Available; Epinephrine Application Denied; Flu Vaccine Efficacy; New Dosing Regimen for Talicia; Change to Generic Tacrolimus
|
Sep 22, 2023 |
|
MPR Weekly Dose 174 — Updated COVID-19 Vaccines; Px Drop for Dry Eye Disease; Crohn Disease Tx Trial; Lotronex Update; FDA Cracks Down on Unapproved Eye Products
|
Sep 15, 2023 |
|
MPR Weekly Dose Podcast #173 — Talking vaccines with Dr. Abdul-Mutakabbir
|
Sep 06, 2023 |
|
MPR Weekly Dose 171 — Vaccine Guidance for Flu Season; PrEP Recommendation; Maternal RSV Vaccine; Latest on Updated COVID Vaccine; CHAPLE Disease Tx Approved
|
Aug 25, 2023 |
|
MPR Weekly Dose 170 — Warning Alert for Tests; Arexy Available for Older Adults; Sohonos and Hezato Kit Approved; Statement on GLP-1 Use Before Endoscopy
|
Aug 18, 2023 |
|
MPR Weekly Dose 169 — New Postpartum Depression Tx; Generic Naloxone Spray; Weight Management Drug Shows Heart Benefits; CDC Recommends RSV Vaccine; SAD Tx
|
Aug 11, 2023 |
|
MPR Weekly Dose 168 — Prescription stimulant shortage; Electronic transfer of controlled substances; Oral contraceptive recall; Ebola vaccine; OTC opioid overdose approval
|
Aug 04, 2023 |
|
MPR Weekly Dose 167 — Molluscum contagiosum Tx approved; Xdemvy and Balfaxar approved; Weight loss drug in short supply; Cervical pessary assessed for reducing preterm birth
|
Jul 28, 2023 |
|
MPR Weekly Dose 166 — Potential Alzheimer drug may slow disease; RSV Tx for neonates, toddlers; Veklury and Brenzavvy approvals expanded; Blood test false negatives
|
Jul 21, 2023 |
|
MPR Weekly Dose 165 — OTC Birth Control Pill; Heart Tx Gains Expanded Approval; Gavreto Indication Withdrawn; Albuterol Inhaler Recall; Paclitaxel-Coated Device Analysis
|
Jul 14, 2023 |
|
MPR Weekly Dose 164 — Approvals for Alopecia, Generalized Myasthenia Gravis, and Type 1 Diabetes; Colonoscopy Prep; FDA Deny Application for Pre-Cirrhotic Fibrosis Tx
|
Jun 30, 2023 |
|
MPR Weekly Dose 163 — COVID-19 Vaccine Authorization Revoked; Injectafer Approved; Lumryz Single Dose for Narcolepsy; Vowst for C. Difficile; Approval for CMV Disease Prevention
|
Jun 08, 2023 |
|
MPR Weekly Dose 162 — LRTD Vaccine; Novel Heart Failure Tx; Compounded Semaglutide Concerns; Opioid Use Disorder Tx; Positive Results for Motion Sickness Tx
|
Jun 02, 2023 |
|
MPR Weekly Dose 161 — First Oral Antiviral Approved for COVID-19; First Topical Tx for Epidermolysis Bullosa; Xacduro and Opvee Approved; Cough Suppressant Recall
|
May 26, 2023 |
|
MPR Weekly Dose 160 — Labeling Update for Prescription Stimulants; Veozah Approved for Vasomotor Symptoms; FDA Vote on DMD Therapy; Fungal Meningitis Cases in US; Child's Smart Thermometer Recalled
|
May 19, 2023 |
|
MPR Weekly Dose 159 — OTC Birth Control Pill Switch; First Tx for Agitation Associated With Dementia; Fabry Disease Treatment; Farxiga Approval Expanded; Contaminated COVID-19 Tests
|
May 12, 2023 |
|
MPR Weekly Dose 158 — Early Alzheimer Treatment; First RSV Vaccine; Narcolepsy Tx; Toilet Seat That Monitors Health; FDA Ammonia Warning
|
May 05, 2023 |
|
MPR Weekly Dose 157 — Akorn Pharmaceutical Recalls; First Oral Fecal Microbiota Tx; ALS Treatment Approved; Basal-Only Insulin Delivery for T2D; Eyedrop Safety Alert
|
Apr 28, 2023 |
|
MPR Weekly Dose 156 — Bivalent COVID-19 Vaccines; Vote on Agitation With Alzheimer Dementia Tx; Descheduled Drug; Migraine Tx Expansion; Restless Legs Syndrome Device
|
Apr 21, 2023 |
|
MPR Weekly Dose 155 — Knee Shock Absorber; Opioid Label Updates; Imbruvica Indications Withdrawn; Patch for Excessive Sweating; Polyclonal Tx for Flu
|
Apr 14, 2023 |
|
MPR Weekly Dose 154 — Novel COVID-19 Tx Granted EUA; Makena Withdrawn; Infant Supine Sleep System; Padcev Plus Keytruda Approved; Opioid Mail-Back Envelopes, Respiratory Depression Detection Device
|
Apr 07, 2023 |
|
MPR Weekly Dose 153 — Diabetes Drugs Discontinued; Trial Results for Schizophrenia Tx; Intranasal Spray Assessed for SAD; High-concentration Humira biosimilar; Inspire Therapy Indication Expanded
|
Mar 24, 2023 |
|
MPR Weekly Dose 152 — Booster Dose Authorized for Under 5s; Rapid STI Test; Rett Syndrome and Migraine Tx Approved; Panel Takes Vote for Polivy Combo
|
Mar 17, 2023 |
|
MPR Weekly Dose 151 — Liver Injury Decline Tied to FDA Rule; Alzheimer Disease Tx Update; Bempedoic Acid in MACE; Blood Test Cleared for TBI Assessment; Mammography Regulatory Update.
|
Mar 10, 2023 |
|
MPR Weekly Dose 150 — Kevzara, Skyclarys Approved; At-Home Combo COVID and Flu Test; Drug-Resistant Shigellosis on Rise; FDA Restrictions on Xylazine-Containing Products
|
Mar 03, 2023 |
|
MPR Weekly Dose 149 — Post-Exposure Molnupiravir Study; Filspari Approved; Treatment for Geographic Atrophy Secondary to AMD Approved; Personalized Melanoma Vaccine; RSV Maternal Vaccine
|
Feb 24, 2023 |
|
MPR Weekly Dose 148 — OTC Narcan; Fecal Microbiota Available; Azithromycin for Postpartum Sepsis; Cibinqo Expanded Approval; Delgocitinib for Hand Eczema
|
Feb 17, 2023 |
|
MPR Weekly Dose 147 — Adlyxin Availability; Zuranolone Priority Review; Recall of Hypothyroidism Treatment; Weight Loss Supplement Warning; First ROP Treatment
|
Feb 10, 2023 |
|
MPR Weekly Dose 146 — Paxlovid, Lagevrio EUA Revised; Beta Blockers and Violence; Jesduvroq Approved; Artificial Tears Product Recall; FDA Halt Use of COVID Therapy
|
Feb 03, 2023 |
|
MPR Weekly Dose 145 — COVID-19 Vaccine Investigation; HIV Vaccine Lacks Efficacy; Sepsis Diagnostic Test; RSV-Associated Disease Vaccine; Combo Tx Reduces CA Recurrence
|
Jan 20, 2023 |
|
MPR Weekly Dose 144 — New Alzheimer disease Tx; Asthma rescue therapy; NERD Tx shows promise; Leukemia drug to be withdrawn; Adacel approved for during pregnancy
|
Jan 13, 2023 |
|
MPR Weekly Dose 143 — Pharmacists can dispense abortion pill; MDMA trial meets endpoints; HIV meds to be discontinued; Obesity Tx approved for children; 2023 best diets rankings
|
Jan 06, 2023 |
|
MPR Weekly Dose 142 — Interview with US News managing health editor, Gretel Schueller
|
Jan 03, 2023 |
|
MPR Weekly Dose 141 — Guidance for Influenza Treatment; Panel Vote on Omecamtiv Mecarbil; Tecentriq Approval; Flu and COVID Combo Vax; Certain COVD Tests Recalled
|
Dec 16, 2022 |
|
MPR Weekly Dose 140 — COVID-19 Vaccines; Narcan for OTC; Diabetes Tx in Peds; Major Depressive Disorder Therapy Fast Tracked; Tecentriq Indication Withdrawn
|
Dec 09, 2022 |
|
MPR Weekly Dose 139 — FDA Pulls COVID-19 Treatment; Amoxicillin Guidance; Fecal Microbiota Treatment Approved; Alzheimer Agitation Tx; Priority Review for DMD Therapy
|
Dec 02, 2022 |
|
MP R Weekly Dose 138 — Elahere Gets Accelerated Approval; Zejula Use Restricted; Update for IUD System; Interchangeable Insulin Products; Panel Votes on Tenapanor
|
Nov 18, 2022 |
|
MPR Weekly Dose 137 — USPSTF Hormone Recommendations; Semaglutide in Obese Teens; Maternal RSV Vaccine Candidate; Antipsychotic REMS Update; Omburtamab Panel Vote
|
Nov 04, 2022 |
|
MPR Weekly Dose 136 — Approvals in Multiple Myeloma, Axial Spondyloarthritis, and Hepatocellular Carcinoma; FDA Panel Vote; Oral Suspension of Tadalafil
|
Oct 28, 2022 |
|
MPR Weekly Dose 135 — Makena Panel Vote; Apixaban vs Rivaroxaban; Monkeypox Ocular Complications; Novavax COVID-19 Booster; Sparsentan, Tofersen Reviews Extended
|
Oct 21, 2022 |
|
MPR Weekly Dose 134 — Vaccine Boosters Authorized; Wearable Furosemide System Approved; Molnupiravir Data; Pertussis Vaccine; FDA Apomorphine Device Update
|
Oct 14, 2022 |
|
MPR Weekly Dose 133 — ALS Treatment Approval; Evusheld Update; At-Home Epilepsy Diagnosis; Clopidogrel, Atenolol Recall; Laser Therapy for Fibromyalgia
|
Oct 07, 2022 |
|
MPR Weekly Dose 132 — Social Media Warning; Cisplatin-Associated Ototoxicity Tx; New Cerebral Adrenoleukodystrophy Tx; MRI Contrast Agent; Generic Tazorac
|
Sep 23, 2022 |
|
MPR Weekly Dose 131 — Approvals in Plaque Psoriasis, Hepatorenal Syndrome and Neutropenia; Priority Review for Rett Syndrome Therapy; Multivitamins Assessed in Cognition
|
Sep 16, 2022 |
|
MPR Weekly Dose 130 — FDA Vote on ALS Treatment; CPAP, BiPAP Recall; CRISPR Therapy for Hereditary Angioedema; Imfinzi Approved for Biliary Tract Cancer; Spevigo Approved
|
Sep 09, 2022 |
|
MPR Weekly Dose 129 — Omicron-Adapted Booster Dose; Influenza Season Guidance; Nirmatrelvir Efficacy; DEA Warn Over "Rainbow Fentanyl"; Chronic Idiopathic Constipation Tx
|
Sep 01, 2022 |
|
MPR Weekly Dose 128 — USPSTF Statin Recommendations; At-Home Visual Test; Novel MDD Treatment; Novavax Authorized in Adolescents; FDA Fecal Microbiota Transplant Alert
|
Aug 26, 2022 |
|
MPR Weekly Dose 127 — Novavax Booster; OTC Hearing Aids; Combo Prostate Cancer Tx; First Gene Therapy for Beta-Thalassemia; Repeat At-Home COVID-19 Testing Needed
|
Aug 19, 2022 |
|
MPR Weekly Dose 126 — Change to Monkeypox Vaccine Supply; Myfembree Indication Expanded; Amazon Among Companies to Receive FDA Warning; Impurity in Diabetes Tx
|
Aug 11, 2022 |
|
MPR Weekly Dose 125 — Device Cleared to Treat C-Section Pain; Plaque Psoriasis Cream; Contrast Agent Shortage Addressed; Lucentis Biosimilar Approved; OTC Laxative Recall Expanded
|
Aug 05, 2022 |
|
MPR Weekly Dose 124 — Novavax Vaccine Gains EUA; Comirnaty Adolescent Approval; OTC Switch for Contraceptive; Nasal Spray Available OTC; Dupilumab for Pediatric EoE
|
Jul 15, 2022 |
|
MPR Weekly Dose MPR 123 — Paxlovid Prescribing; Evusheld Dosing Updates; New Abuse-Deterrent Opioid; Lecanemab Priority Review; Morphine Tablet Recall
|
Jul 07, 2022 |
|
MPR Weekly Dose MPR 122 — Nasal Spray for Allergic Rhinitis; Qsymia Approval Expanded; Monkeypox Vaccine; Antibodies Shelf Life Extended; FDA Ban JUUL Products
|
Jul 01, 2022 |
|
MPR Weekly Dose MPR 121 — New Treatment for Crohn Disease; USPSTF Recommendations on Vitamins for CVD, CA Prevention; Panel Vote on Alzheimer Tx; Phexxi Analysis; Vaxneuvance Approved for Pediatrics
|
Jun 24, 2022 |
|
MPR Weekly Dose MPR 120 — Child COVID Vaccine Vote; Alopecia Tx Approved; Paxlovid in Standard Risk Patients; Autism Diagnostic Aid; Polyneuropathy hATTR Amyloidosis
|
Jun 17, 2022 |
|
MPR Weekly Dose MPR 119 — FDA Panel Votes on Novavax; MMR Vaccination; Dupixent Approval Expanded; Investigative COVID-19 Treatments
|
Jun 10, 2022 |
|
MPR Weekly Dose 118 — Ukoniq Approval Withdrawn; Rescue Inhaler to Be Reviewed; Dupilumab Priority Review; Kymriah Update; Novel Postpartum Depression Tx Shows Promise
|
Jun 03, 2022 |
|
MPR Weekly Dose 117 — Guidance on Paxlovid Tx; Dupixent Approval; Plaque Psoriasis Cream Approved; COVID-19 Vaccine Response in Under 5s; CDC Monkeypox Alert
|
May 27, 2022 |
|
MPR Weekly Dose 116 — First-in-Class T2D Treatment; FDA Decline Fluvoxamine; Booster Doses for Children; COVID-19, Influenza, and RSV Test; Wearable Furosemide Delivery System
|
May 20, 2022 |
|
MPR Weekly Dose 115 — Janus Kinase Inhibitor Approved for COVID-19; Varenicline Supply; Janssen Vaccine Limits Set; Test Safety Alert; Potential Hemodialysis Chemical Exposure
|
May 12, 2022 |
|
MPR Weekly Dose 114 - USPSTF Aspirin Recommendations; COVID-19 treatment expansion; Accupril Recall; Counterfeit HIV Meds; White House Plan to Tackle Overdose Epidemic
|
Apr 29, 2022 |
|
MPR Weekly Dose 113 - Sabizabulin Trial Stopped; Booster Request for Peds; Diversity in Clinical Trials; Myopericarditis Risks Compared for Vaccines; Approval Effect on the Unvaccinated
|
Apr 15, 2022 |
|
MPR Weekly Dose 112 - Second COVID-19 Booster Dose Authorized; Sotrovimab Use Limited; Oral COVID-19 Tx; PreHevbrio Hep B Vaccination; Thyroid Dysfunction Alert Following ICM
|
Apr 01, 2022 |
|
MPR Weekly Dose 111 - Allergy Spray OTC Switch; Syringe Malfunction Prompts Recall; Sciatica Pain Tx Update; FDA Alert for COVID-19 Tests; Resubmitted Teplizumab Application Accepted
|
Mar 25, 2022 |
|
MPR Weekly Dose #110: Interview With Dr Tobias Janowitz
|
Mar 18, 2022 |
|
MPR Weekly Dose 109 - Purdue Overdose Treatment Approved; ACIP Immunization Schedules; FDA Provide List of COVID-19 Tests; Urticaria Trial Stopped; First Condom for Anal Intercourse.
|
Feb 25, 2022 |
|
MPR Weekly Dose 108 - OTC Treatment Shows Benefit in COVID-19; Emergency Use Granted to Antibody; Parkinson Disease Tx Available; Veklury Study Results; Safety Concern for Ketamine
|
Feb 18, 2022 |
|
MPR Weekly Dose 107 - Millions of Molnupiravir Courses Delivered; Guidance on Nonopioid Analgesic Development; Enteral Feeding Tube Warning; Enjaymo Approved; Mecarbil Under Review for HFrEF
|
Feb 11, 2022 |
|
MPR Weekly Dose 106 - FDA Approves COVID-19 Vaccine; EUA Submission for Kids Under 5; COVID Tests Recalled; Vupanorsen Development Ends; Cabenuva Approval Expanded
|
Feb 03, 2022 |
|
MPR Weekly Dose 105 - Antibody Therapies Restricted; Veklury Greenlit for Outpatients; Parsaclisib Indication Withdrawn; Pepaxto Withdrawal Reconsidered; Kimmtrak Approved
|
Jan 28, 2022 |
|
MPR Weekly Dose 104 - Two New Atopic Dermatitis Therapies; Counterfeit HIV; Indications Withdrawn for Zydelig; CDC Pediatric Influenza Vaccine Study Results; COVID Test Warning
|
Jan 20, 2022 |
|
MPR Weekly Dose 103 - Novel treatment for insomnia; Magnesium health claim; Dental decay and transmucosal med; Vaccine and menstrual cycle findings; Best diets for 2022
|
Jan 13, 2022 |
|
MPR Weekly Dose 102 - COVID-19 vaccine contraindication; Final results for COVID-19 antiviral; Entadfi approved; CAR T-cell REMS change; New approval for psoriatic arthritis
|
Dec 17, 2021 |
|
MPR Weekly Dose 101 - COVID-19: Pre-exposure prophylaxis approved; Omicron vaccine protection; Antibody authorized for kids; Heterolous boosting assessed; Veklury recall
|
Dec 10, 2021 |
|
MPR Weekly Dose 100 - Paxlovid EUA submission; Drugs linked to orthostatic hypotension; Besremi approved; Pill for remote endoscopy; Largest psilocybin trial to date
|
Nov 19, 2021 |
|
MPR Weekly Dose 99 - Oral COVID-19 candidate reduces risk of death; aromatherapy sprays recalled; Presbyopia Tx; Naloxone alternative; Migraine drug head-to-head study
|
Nov 12, 2021 |
|
MPR Weekly Dose 98 - FDA Committee Vote on Vaccines for Children; Booster Efficacy Results; Shingrix Recommendations; Novel Treatment for Macular Edema; Pepaxto Withdrawn
|
Oct 29, 2021 |
|
MPR Weekly Dose 97 - 'Mix and Match' Boosters Authorized; Biosimilar to Humira; Nasal Spray for Dry Eye Disease; Novel Pain Treatment; Opioid Overdose Treatment
|
Oct 22, 2021 |
|
MPR Weekly Dose 96 - Updated Aspirin Recommendations; Needle-Free Warning; Isotretinoin REMS program; Pediatric Athymia Tx; EU Request for Molnupiravir; Advisory Panel Votes on Moderna Booster Shot
|
Oct 15, 2021 |
|
MPR Weekly Dose 95 - Interview with Dr Preeti Malani, Chief Health Officer and Professor of Medicine in the Division of Infectious Diseases at the University of Michigan
|
Oct 07, 2021 |
|
MPR Weekly Dose 94 - COVID Vaccine Booster Doses; Pediatric Vaccine Trial; Parental Vaccine Hesitancy; Remdesivir and Hospitalization Risk; Atopic Dermatitis Treatment
|
Sep 24, 2021 |
|
MPR Weekly Dose 93 - Mandatory Opioid Prescriber Education; Rise in Delta-8 THC Products; Brukinsa and Exkivity Approved; Warning Letters for Supplement Companies
|
Sep 17, 2021 |
|
MPR Weekly Dose 92 - AAP Vaccination Guidance; Moderna Booster; JAK Inhibitor Warnings; New Migraine Treatment Nasal Spray; Hold Placed on Phenylketonuria
|
Sep 10, 2021 |
|
MPR Weekly Dose 91 - First Full COVID-19 Vaccine Approval; Pfizer Submit for Third Dose; AAP Advises on Off-Label Vaccinations; COVID Antibody Tx; Moderna BLA Submission
|
Aug 26, 2021 |
|
MPR Weekly Dose 90 - COVID-19 Vaccine Booster Dose; Vaccine for Tick-Borne Encephalitis; Jardiance Approval; FDA Wristband Warning; Jemperli Accelerated Approval
|
Aug 19, 2021 |
|
MPR Weekly Dose 89 - COVID Vaccine Booster Dose; Vaccines Recommended in Pregnancy; Post-Vaccine Myocarditis Study; Moderna Efficacy at 6 Months; Pompe Disease Tx; FDA Denies Roxadustat
|
Aug 13, 2021 |
|
MPR Weekly Dose 88 - Postexposure Tx for COVID-19; Novel lupus treatment; Higher dose naloxone; Clozapine REMS changes; Istodax indication withdrawn
|
Aug 06, 2021 |
|
MPR Weekly Dose 87 - Statin contraindication change; Vaccine for streptococcus pneumoniae; Plaque psoriasis cream; Therapy fast tracked for Parkinson disease; Bylvay approved
|
Jul 23, 2021 |
|
MPR Weekly Dose Podcast Episode 86
|
Jul 16, 2021 |
|
MPR Weekly Dose 85 - Chantix recalled; Kimyrsa for ABSSSI; Aduhelm label update; Blood lead test recall; Keytruda changes
|
Jul 09, 2021 |
|
MPR Weekly Dose 84 - Emergency Use for COVID-19 treatment; Fact sheet update for vaccines; Rylaze approved; Expanded approval for Solosec; NDA submitted for HIV-1 treatment
|
Jul 02, 2021 |
|
MPR Weekly Dose 83 - Rx-to-OTC for allergy spray; Novel contraceptive; Pediatric VTE Tx; Veklury real world efficacy data; Wearable thermometer
|
Jun 24, 2021 |
|
MPR Weekly Dose 82 - A regenerative skin therapy; Novavax vaccine shows promise; Mastocytosis treatment; Potential new depression treatment; And an FDA warning for hand sanitizers.
|
Jun 17, 2021 |
|
MPR Weekly Dose 81 - A first therapy to target underlying process of Alzheimer disease; Moderna requests EUA; And a list of new approvals in a variety of therapeutic categories
|
Jun 11, 2021 |
|
MPR Weekly Dose 80 - Migraine prevention treatment; Pediatric combo vaccine; Schizophrenia, Bipolar I approval; AI-based Autism diagnostic
|
Jun 04, 2021 |
|
MPR Weekly Dose 79 - COVID-19: vaccine storage, efficacy updates; Gene therapy Fast Tracked; Vitiligo cream trial results; Aspirin dosage compared in ASCVD
|
May 21, 2021 |
|
MPR Weekly Dose 78 - Vaccine authorized for adolescents; Postoperative pain Tx approval; Insulin products recalled; Treatment Fast Tracked for facioscapulohumeral muscular dystrophy
|
May 14, 2021 |
|
MPR Weekly Dose 77 - Updated mask guidance; Janssen vaccine resumption; Steroid therapy in COVID-19; Novel MDD gains Priority Review; Scabies treatment; Stroke rehabilitation device
|
Apr 30, 2021 |
|
MPR Weekly Dose 76 - Bamlanivimab emergency use changes; Janssen vaccine facilities; Molnupiravir trial halted; New contraceptive approved; Ragweed pollen allergy treatment
|
Apr 23, 2021 |
|
MPR Weekly Dose 75 - Janssen vaccine on pause; Antibody therapy guidance; Remote mifepristone dispensing; Xolair self-administration; And a new AI colonoscopy system
|
Apr 16, 2021 |
|
MPR Weekly Dose 74 - Updated travel guidance; Six month vaccine efficacy data; Increased Moderna doses per vial; New ADHD treatment; And a safety communication for lamotrigine
|
Apr 09, 2021 |
|
MPR Weekly Dose #73: Interview with Dr Joshua Barocas
|
Mar 30, 2021 |
|
MPR Weekly Dose 72 - Real world vaccine effectiveness; Two-dose completion data; Moderana pediatric trial; Results from tocilizumab plus remdesivir trial; Kimyrsa approved.
|
Mar 18, 2021 |
|
MPR Weekly Dose 71 - Guidance for those fully vaccinated; A first in COVID-19 testing; Povidone Iodine and Bamlanivimab-Etesevimab examined; Delayed local vaccine reactions
|
Mar 12, 2021 |
|
MPR Weekly Dose 70 - Keytruda indication withdrawn; Janssen's single-shot vaccine gains EUA; Ivermectin assessed for mild COVID-19; FDA clears wearables
|
Mar 05, 2021 |
|
MPR Weekly Dose #69 - False and misleading pharma promo; Novel LDL-C therapy; Heart failure Tx expanded; Migraine device okay'd for teens.
|
Feb 18, 2021 |
|
MPR Weekly Dose #68 - Remdesivir compounding; Emergency Use Authorizations; Sleep apnea device; New Botox approval
|
Feb 12, 2021 |
|
MPR Weekly Dose #67 - Efficacy data for AstraZeneca, J&J and Novovax vaccines; Approvals in analgesia and influenza.
|
Feb 05, 2021 |
|
MPR Weekly Dose 66 - The Moderna vaccine's efficacy against new variants; Merck ends development of new vaccines; Antiviral treatment combos show promise; New lupus nephritis treatment
|
Jan 28, 2021 |
|
MPR Weekly Dose #65 - Johnson & Johnson's vaccine candidate; Blood donations during pandemic; New Tx for heart failure with reduced ejection fraction; A potential Alzheimer drug; Changes to vinca alkaloid labeling
|
Jan 22, 2021 |
|
MPR Weekly Dose #64 - Pfizer-BioNTech vaccine efficacy against new variant; Ravulizumab trial halted; Rapid concussion test; Novel chronic kidney disease Tx; NSAID recalled
|
Jan 15, 2021 |
|
MPR weekly dose #63 - COVID-19 vaccine admin scheduling and production updates; A diagnostic test that is giving false negative results; Bristol Myers Squibb withdraws an indication for Opdivo; And experts vote on the best diets for 2021.
|
Jan 08, 2021 |
|
MPR Weekly Dose #62 - Major vaccine developments; FDA authorizes rapid at-home COVID test; New findings for glucosamine supplementation; And a novel budesonide oral suspension gets Priority Review
|
Dec 18, 2020 |
|
MPR Weekly Dose #61 - Sitagliptin findings in pediatrics; Obesity treatment gains expanded approval; The FDA issue a CRL; And a new transdermal contraceptive
|
Dec 11, 2020 |
|
MPR Weekly Dose #60 - The FDA stand by remdesivir; Who should get the vaccine first? Xolair and Hetlioz gain expanded approvals; And a novel neuroblastoma treatment
|
Dec 04, 2020 |
|
MPR Weekly Dose #59 - The latest on vaccine news from Moderna, and BioNTech and Pfizer as they release more trial data; A at-home diagnostic test; Keytruda gains expanded approval; and more
|
Nov 20, 2020 |
|
MPR Weekly Dose #58 - Major developments in COVID vaccine and antibody treatments; Also an FDA Advisory Committee vote on what would be the first Alzheimer drug in decades.
|
Nov 13, 2020 |
|
MPR Weekly Dose #57 - NDA in diabetes; Post-op implant pain Tx; DEA schedules new opioid; FDA lists 200+ drugs; Rifaximin and other drugs in the pipeline news
|
Nov 06, 2020 |
|
MPR Weekly Dose Episode #56 - Antibody responses; Convalescent plasma; Nasal spray for diabetic gastroparesis; Colorectal cancer screening recommendations; New dry eye treatment; And movie trivia!
|
Oct 30, 2020 |
|
MPR Weekly Dose Podcast Episode 55
|
Oct 23, 2020 |
|
Weekly Dose #54 - Vaccine trial halted; Hyperimmune trial begins; IV tramadol rejected; FDA votes on schizophrenia, bipolar Tx; And a first in Ebola treatment
|
Oct 16, 2020 |
|
Weekly Dose #53 - Encouraging news on antibody therapies; EUA guidelines for potential vaccines; Remdesivir distribution; The HIV drug that failed to have an impact; And the preterm birth treatment the FDA want withdrawn from the market.
|
Oct 09, 2020 |
|
Weekly Dose #52 – New Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok 'Challenge'; And FDA grants Nucala new approval.
|
Oct 02, 2020 |
|
MPR Weekly Dose Podcast Episode 51
|
Sep 18, 2020 |
|
Weekly Dose #50 - Pause on vaccine trial; Benefits for steroid therapy in COVID patients; Higher doses of diabetes treatment okay'd; First non-hormonal contraceptive; FDA issue SCS warning
|
Sep 11, 2020 |
|
Weekly Dose #49 - ACIP vaccine guidelines; Convalescent plasma; 15 minute test; Plant warning; Intrauterine device; Hydrochlorothiazide
|
Aug 28, 2020 |
|
Pneumonia Associated COVID-19; Inaccurate Tests; Neck Gaiters; Drug Applications Halted; Narcan Update
|
Aug 21, 2020 |
|
Weekly Dose #47: Remdesiver news; New opioid, SMA treatments; Sublingual epinephrine; Alzheimer treatment
|
Aug 14, 2020 |
|
COVID Vaccine Developments; Long-Term Facility Study; Cannabidiol; New Depression Treatment; Peanut Allergy Rejection
|
Aug 07, 2020 |
|
MPR Weekly Dose Podcast Episode 45
|
Jul 31, 2020 |
|
MPR Weekly Dose Podcast Episode 44
|
Jul 24, 2020 |
|
MPR Weekly Dose Podcast Episode 43
|
Jul 17, 2020 |
|
MPR Weekly Dose Podcast Episode 42
|
Jul 09, 2020 |
|
MPR Weekly Dose Podcast Episode 41
|
Jul 02, 2020 |
|
MPR Weekly Dose Podcast Episode 40
|
Jun 26, 2020 |
|
MPR Weekly Dose Podcast Episode 39
|
Jun 19, 2020 |
|
MPR Weekly Dose Podcast Episode 38
|
Jun 12, 2020 |
|
MPR Weekly Dose Podcast Episode 37
|
Jun 05, 2020 |
|
MPR Weekly Dose Podcast Episode 36
|
May 29, 2020 |
|
MPR Weekly Dose Podcast Episode 35
|
May 22, 2020 |
|
MPR Weekly Dose Podcast Episode 34
|
May 14, 2020 |
|
MPR Weekly Dose Podcast Episode 33
|
May 07, 2020 |
|
MPR Weekly Dose Podcast Episode 32
|
Apr 30, 2020 |
|
MPR Weekly Dose Podcast Episode 31
|
Apr 23, 2020 |
|
MPR Weekly Dose Podcast Episode 30
|
Apr 17, 2020 |
|
MPR Weekly Dose Podcast Episode 29
|
Apr 09, 2020 |
|
MPR Weekly Dose Podcast Episode 28
|
Apr 03, 2020 |
|
MPR Weekly Dose Podcast Episode 27
|
Mar 27, 2020 |
|
MPR Weekly Dose Podcast Episode 26
|
Mar 20, 2020 |
|
MPR Weekly Dose Podcast Episode 25
|
Mar 12, 2020 |
|
MPR Weekly Dose Podcast Episode 24
|
Mar 05, 2020 |
|
MPR Weekly Dose Podcast Episode 23
|
Feb 27, 2020 |
|
MPR Weekly Dose Podcast Episode 22
|
Feb 20, 2020 |
|
MPR Weekly Dose Podcast Episode 21
|
Feb 13, 2020 |
|
MPR Weekly Dose Podcast Episode 20
|
Feb 06, 2020 |
|
MPR Weekly Dose Podcast Episode 19
|
Jan 30, 2020 |
|
MPR Weekly Dose Podcast Episode 18
|
Jan 24, 2020 |
|
MPR Weekly Dose Podcast Episode 17
|
Jan 16, 2020 |
|
MPR Weekly Dose Podcast Episode 16
|
Jan 10, 2020 |
|
MPR Weekly Dose Podcast Episode 15
|
Dec 05, 2019 |
|
MPR Weekly Dose Podcast: Episode 14
|
Nov 22, 2019 |
|
MPR Weekly Dose Podcast Episode 13
|
Nov 14, 2019 |
|
MPR Weekly Dose Podcast Episode 12
|
Nov 08, 2019 |
|
MPR Weekly Dose Podcast: Episode 11
|
Nov 01, 2019 |
|
MPR Weekly Dose Podcast Episode 10
|
Oct 24, 2019 |
|
MPR Weekly Dose Podcast Episode 9
|
Oct 17, 2019 |
|
MPR Weekly Dose Podcast Episode 8
|
Oct 11, 2019 |
|
MPR Weekly Dose Podcast: Episode 7
|
Oct 04, 2019 |
|
MPR Weekly Dose Podcast: Episode 6
|
Sep 26, 2019 |
|
MPR Weekly Dose Podcast: Episode 5
|
Sep 20, 2019 |
|
MPR Weekly Dose Podcast: Episode 3
|
Aug 30, 2019 |
|
MPR Weekly Dose Podcast: Episode 2
|
Aug 23, 2019 |
|
MPR Weekly Dose Podcast: Episode 1
|
Aug 19, 2019 |